Literature DB >> 6943388

[Presentation of the cooperative study COALL-80 on treatment of childhood ALL (author's transl)].

K Winkler, E Matzke, S Caspers, R Erttmann, I Grosch-Wörner, H Kabisch, J Müller, G Landbeck.   

Abstract

The cooperative study COALL-80 is derived from the BFM-78-study. The aim of the study is a reduction of the initial therapy-morbidity and -mortality without loss of efficacy by omitting asparaginase from the four drug-induction regimen and interposing it between induction- and CNS-therapy phase. The expected two years disease free survival rate of a pilot study will be 82%. This finding is hitherto comparable with the BFM-study results.

Mesh:

Substances:

Year:  1981        PMID: 6943388     DOI: 10.1055/s-2008-1034451

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  1 in total

1.  Intermediate-dose methotrexate in the treatment of childhood acute lymphocytic leukaemia: lack of benefit during maintenance therapy following intensive induction therapy.

Authors:  G E Janka-Schaub; K Winkler; H Jürgens; U Goebel; P Gutjahr; H J Spaar
Journal:  Eur J Pediatr       Date:  1986-04       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.